Get the Stockscreener App
59.75
1.11%
-0.67
Pre-market:
59.25
-0.50
-0.84%
Moderna Inc stock is traded at $59.75, with a volume of 6.17M.
It is down -1.11% in the last 24 hours and up +27.45% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$60.42
Open:
$60.33
24h Volume:
6.17M
Relative Volume:
0.91
Market Cap:
$23.71B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-7.3347
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-6.58%
1M Performance:
+27.45%
6M Performance:
+82.44%
1Y Performance:
+122.45%
1-Day Range:
$57.91
$61.86
1-Week Range:
$57.50
$65.51
52-Week Range:
$22.28
$67.74
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
59.75 | 23.97B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
480.18 | 120.61B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
620.14 | 65.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.65 | 53.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.17 | 39.26B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
178.17 | 36.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst - The Globe and Mail
Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside - TradingView
Moderna Upbeat on New Flu Shot to Help Educate Public About MRNA - Bloomberg.com
Moderna outlines next phase of mRNA expansion beyond vaccines - The Pharma Letter
Price to book forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Enterprise value to EBIT forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna (MRNA) Unveils Strategic Development Goals at Science Da - GuruFocus
Moderna updates pipeline with CAR-T program for autoimmune diseases By Investing.com - Investing.com Canada
Enterprise value to EBITDA forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna outlines mRNA pipeline progress at Science Day event - StreetInsider
Moderna says its mRNA pipeline now spans cancer and autoimmune disease - Stock Titan
Friedenthal Financial Invests $1.10 Million in Moderna, Inc. $MRNA - MarketBeat
Hsbc Holdings PLC Sells 107,077 Shares of Moderna, Inc. $MRNA - MarketBeat
Enterprise value to revenue forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
FDA Panel Backs Moderna's First mRNA Flu Shot — What It Could Mean for Your Fall Vaccine - Medical Daily
How Unanimous FDA Panel Support For mRNA Flu Shot At Moderna (MRNA) Has Changed Its Investment Story - Yahoo Finance
Moderna rallies on vaccine progress as investors await revenue growth - Traders Union
Moderna: Flu Vaccine Progress Is Only Part Of The Story (NASDAQ:MRNA) - Seeking Alpha
Moderna adjusts to efficiency push, shares track next earnings test - Ad-hoc-news.de
(MRNA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Moderna advances after flu vaccine panel vote, shares extend June rebound on NASDAQ - Ad-hoc-news.de
Merck & Co. updates cancer pipeline strategy, shares supported by post-Keytruda focus - Ad-hoc-news.de
MRNA Stock Jumps As Flu Win And Expansion Fuel Momentum - timothysykes.com
Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade) (NASDAQ:MRNA) - Seeking Alpha
MRNA Stock Jumps As FDA Backs Flu Shot And Expansion Plans - StocksToTrade
Moderna: The Comeback Is Now In Full Swing (NASDAQ:MRNA) - Seeking Alpha
FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine - WSJ
Should You Buy Moderna Before Aug. 5? - The Motley Fool
Should You Buy Moderna Before Aug. 5? - The Motley Fool
Moderna, Inc.’s stock price dips to $59.34, marking a 7.22% downturn: Is it time to buy? - Smartkarma
MRNA Stock Quote Price and Forecast - CNN
Gov't Says It Should Face Vax IP Claims, Not Moderna - Law360
Moderna Stock’s 6-Day Rally Ends in a Dive. Why It’s One of the S&P 500’s Biggest Losers Today. - Barron's
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Moderna (MRNA) - The Globe and Mail
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway - Yahoo Finance
Leerink Partners Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating - marketscreener.com
Moderna Stock On Fire: Up 39% With 6-Day Winning Streak - Trefis
Moderna Stock 6-Day Winning Spree: Stock Climbs 39% - Trefis
FDA approves Moderna's new mRNA-based flu vaccine - The Jerusalem Post
FDA Panel Backs Moderna’s mRNA-Based Influenza Vaccine for Adults 50+ - Medical Professionals Reference
Moderna (MRNA) Receives Unanimous FDA Panel Support for Flu Vacc - GuruFocus
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy? - AOL.com
Virtu Financial LLC Takes $2.42 Million Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Tobam - MarketBeat
FDA panel backs first-of-its-kind flu vaccine using mRNA technology - Los Angeles Times
FDA AdCom unanimously backs Moderna’s mFlusiva - The Pharmaletter
mRNA Patent Wars Update: Delaware Court Allows Moderna and Pfizer/BioNTech to Assert Laches in GSK Patent Infringement Cases - JD Supra
FDA panel supports first mRNA-based flu vaccine - National News Desk
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):